Juan F VÃzquez Costa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3853119/publications.pdf

Version: 2024-02-01

60 papers 1,015 citations

471061 17 h-index 28 g-index

70 all docs

70 docs citations

times ranked

70

1385 citing authors

#	Article	IF	CITATIONS
1	Charcot-Marie-Tooth disease. Neurology, 2013, 81, 1617-1625.	1.5	115
2	Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation. Neurology, 2021, 97, e1809-e1822.	1.5	61
3	Analysis of the <i>CHCHD10 </i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	3.7	56
4	Quantitative Muscle Ultrasonography Using Textural Analysis in Amyotrophic Lateral Sclerosis. Ultrasonic Imaging, 2017, 39, 357-368.	1.4	43
5	Muscular Echovariation: A New Biomarker in Amyotrophic Lateral Sclerosis. Ultrasound in Medicine and Biology, 2017, 43, 1153-1162.	0.7	42
6	Measuring Outcomes in Adults with Spinal Muscular Atrophy – Challenges and Future Directions – Meeting Report. Journal of Neuromuscular Diseases, 2020, 7, 523-534.	1.1	39
7	Distal hereditary motor neuropathies: Mutation spectrum and genotype–phenotype correlation. European Journal of Neurology, 2021, 28, 1334-1343.	1.7	39
8	Quantitative neuromuscular ultrasound analysis as biomarkers in amyotrophic lateral sclerosis. European Radiology, 2019, 29, 4266-4275.	2.3	37
9	Late clinical and radiological complications of stereotactical radiosurgery of arteriovenous malformations of the brain. Neuroradiology, 2013, 55, 405-412.	1.1	35
10	Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2018, 12, 784.	1.4	35
11	Lipopolysaccharide-induced radical formation in the striatum is abolished in Nox2 gp91phox-deficient mice. Journal of Neural Transmission, 2010, 117, 13-22.	1.4	28
12	New insights into the pathophysiology of fasciculations in amyotrophic lateral sclerosis: An ultrasound study. Clinical Neurophysiology, 2018, 129, 2650-2657.	0.7	28
13	Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2018, 137, 262-271.	1.0	27
14	Monitoring Progression of Amyotrophic Lateral Sclerosis Using Ultrasound Morpho-Textural Muscle Biomarkers: A Pilot Study. Ultrasound in Medicine and Biology, 2018, 44, 102-109.	0.7	27
15	Local stimulation of the adenosine A _{2B} receptors induces an increased release of ILâ€6 in mouse striatum: an <i>in vivo</i> microdialysis study. Journal of Neurochemistry, 2008, 105, 904-909.	2.1	24
16	Postradiosurgery Hemorrhage Rates of Arteriovenous Malformations of the Brain. Stroke, 2012, 43, 1247-1252.	1.0	22
17	Urodynamic findings in amyotrophic lateral sclerosis patients with lower urinary tract symptoms: Results from a pilot study. Neurourology and Urodynamics, 2017, 36, 626-631.	0.8	21
18	Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder. Journal of the Neurological Sciences, 2017, 378, 130-136.	0.3	17

#	Article	IF	CITATIONS
19	Age at surgery as a predictor of cognitive improvements in patients with drug-resistant temporal epilepsy. Epilepsy and Behavior, 2017, 70, 10-17.	0.9	16
20	Facial Onset Sensory and Motor Neuronopathy. Neurology: Clinical Practice, 2021, 11, 147-157.	0.8	16
21	Phenotype and natural history of inherited neuropathies caused by <i>HSJ1 </i> c.352+1G> A mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1265-1268.	0.9	15
22	Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying <i>MME</i> mutations. Journal of Medical Genetics, 2018, 55, 814-823.	1.5	15
23	Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study. Journal of Neurology, 2016, 263, 1954-1960.	1.8	14
24	Ultrasoundâ€guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients. European Journal of Neurology, 2021, 28, 676-680.	1.7	14
25	Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene. Journal of the Neurological Sciences, 2018, 387, 134-138.	0.3	13
26	Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study. Frontiers in Neurology, 2020, 11, 604922.	1.1	13
27	Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study). Neurology and Therapy, 2021, 10, 361-373.	1.4	13
28	Sonoelastography for the Assessment of Muscle Changes in Amyotrophic Lateral Sclerosis: Results of a Pilot Study. Ultrasound in Medicine and Biology, 2018, 44, 2540-2547.	0.7	12
29	Mesencephalic area measured by transcranial sonography in the differential diagnosis of parkinsonism. Parkinsonism and Related Disorders, 2013, 19, 732-736.	1.1	11
30	Minimal detectable change and minimal clinically important difference in spinal muscular atrophy patients. European Journal of Neurology, 2021, 28, e40-e41.	1.7	11
31	The Study of Deep Brain Structures by Transcranial Duplex Sonography and Imaging Resonance Correlation. Ultrasound in Medicine and Biology, 2013, 39, 226-232.	0.7	10
32	Facial onset sensory and motor neuronopathy: a motor neuron disease with an oligogenic origin?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 172-175.	1.1	10
33	Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases, 2021, 8, 543-551.	1.1	9
34	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rg 821-831.	gBT /Overlo 4.9	ock 10 Tf 50 9
35	Natural history data in adults with SMA. Lancet Neurology, The, 2020, 19, 564-565.	4.9	8
36	Clinical spectrum of BICD2 mutations. European Journal of Neurology, 2020, 27, 1327-1335.	1.7	8

#	Article	IF	CITATIONS
37	A study of the phenotypic variability and disease progression in Laing myopathy through the evaluation of muscle imaging. European Journal of Neurology, 2021, 28, 1356-1365.	1.7	8
38	Pediatric inherited peripheral neuropathy: a prospective study at a Spanish referral center. Annals of Clinical and Translational Neurology, 2021, 8, 1809-1816.	1.7	7
39	Primary lateral sclerosis and hereditary spastic paraplegia in sporadic patients. An important distinction in descriptive studies Annals of Neurology, 2016, 80, 169-170.	2.8	6
40	Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity. Scientific Reports, 2017, 7, 7119.	1.6	6
41	Charcot–Marie–Tooth disease due to <i>MORC2</i> mutations in Spain. European Journal of Neurology, 2021, 28, 3001-3011.	1.7	6
42	The width of the third ventricle associates with cognition and behaviour in motor neuron disease. Acta Neurologica Scandinavica, 2019, 139, 118-127.	1.0	5
43	Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus). NeurologÃa (English Edition), 2022, 37, 216-228.	0.2	4
44	AngiopatÃa amiloide inflamatoria. NeurologÃa, 2014, 29, 254-256.	0.3	3
45	Clinical and neuroimaging characterization of two C9orf72-positive siblings with amyotrophic lateral sclerosis and schizophrenia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 297-300.	1.1	3
46	Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community. NeurologÃa (English Edition), 2020, 36, 504-513.	0.2	3
47	Presenilin-1 Mutations Are a Cause of Primary Lateral Sclerosis-Like Syndrome. Frontiers in Molecular Neuroscience, 2021, 14, 721047.	1.4	3
48	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
49	The role of <i>DNAJB2 </i> ii amyotrophic lateral sclerosis. Brain, 2016, 139, e57-e57.	3.7	2
50	Tratamiento de pacientes con atrofia muscular espinal 5q: hacia un nuevo protocolo. NeurologÃa, 2020, 36, 636-636.	0.3	2
51	Imaging Biomarkers in Amyotrophic Lateral Sclerosis. Neuromethods, 2022, , 507-548.	0.2	2
52	MejorÃa de la espasticidad en esclerosis lateral primaria tras la inyección de toxina botulÃnica. A propósito de un caso. NeurologÃa, 2018, 33, 131-133.	0.3	1
53	Moral reasoning and moral conflict in patients of the amyotrophic lateral sclerosis – Frontotemporal dementia spectrum. Social Neuroscience, 2020, 15, 668-677.	0.7	1
54	A novel <i>TRMT5</i> mutation causes a complex inherited neuropathy syndrome: The role of nerve pathology in defining a demyelinating neuropathy. Neuropathology and Applied Neurobiology, 2022, 48, e12817.	1.8	1

#	Article	IF	CITATIONS
55	The cross-sectional area of the median nerve: An independent prognostic biomarker in amyotrophic lateral sclerosis. Neurolog $ ilde{A}$ a, 2022, , .	0.3	1
56	Inflammatory amyloid angiopathy. NeurologÃa (English Edition), 2014, 29, 254-256.	0.2	0
57	Urinary symptoms in patients with amyotrophic lateral sclerosis. NeurologÃa (English Edition), 2020, 35, 505-506.	0.2	0
58	SÃntomas urinarios en pacientes con esclerosis lateral amiotrófica. NeurologÃa, 2020, 35, 505-506.	0.3	0
59	Treatment of patients with spinal muscular atrophy 5q: towards a new protocol. NeurologÃa (English) Tj ETQq1	1 0,784314 0.2	4 rgBT /Overl
60	Role of the nigrosome 1 absence as a biomarker in amyotrophic lateral sclerosis. Journal of Neurology, 2021, , 1.	1.8	0